China Resources Pharmaceutical Group and CrystecPharma enter agreement to bridge research and innovation between China and the UK

Aug 24, 2017

Crystec’s Chief Scientist, Prof. Peter York, and China Resources Pharmaceutical’s President, Mr. Wang Chuncheng, were hosted by the UK Department of International Trade to sign a strategic cooperation agreement.

The China-UK Research & Innovation Bridge was established in 2016 between the Ministry of Science and Technology in China, and InnovateUK in the United Kingdom. Ultimately, it aims to foster collaborative technology and development platforms between the two nations in a range of areas, including Healthcare.

As part of this programme, Mr. Wang Chuncheng, President of China Resources Pharmaceutical Group and Prof. Peter York, Chairman at CrystecPharma, signed a strategic cooperation agreement at the UK Department of International Trade in London. Matthew Speers, Director of Life Sciences at the UK Department of International Trade, presided over the signing ceremony, and Mr. Zhang Bin, Business Counselor of the Chinese Embassy in UK, attended the event as a special guest.

The programme will focus on decreasing the burden of severe respiratory diseases in China, including chronic obstructive pulmonary disease (COPD), through application of Crystec’s mSAS (modified supercritical anti-solvent) technology platform. The project will also be supported by The Shanghai Institute of Materia Medica.

For more information please contact Emily Bevis (emily.bevis@crystecpharma.com) or Wenwen Zhao (wenwen.zhao@crystecpharma.com). 

To keep up to date with the latest news from Crystec, please follow us on LinkedIn.